Drug Combination Details
| General Information of the Combination (ID: C10758) | |||||
|---|---|---|---|---|---|
| Name | Genistein NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
|
Melanoma
[ICD-11: 2C30]
|
Investigative | [2] | |||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [3] | |||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [4] | |||
|
Colon cancer
[ICD-11: 2B90]
|
Investigative | [5] | |||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [6] | |||
|
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [7] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [5] | |||||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Genistein modulates the anti-tumor activity of cisplatin in MCF-7 breast and HT-29 colon cancer cells. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [6] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | PIK3CB | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| In-vivo Model | The exponentially growing A549 cells were harvested and a tumorigenic dose of 2.5*106 cells was injected intraperitoneally into the 4-5 week-old mice. | |||||
| Experimental
Result(s) |
Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo. | |||||
| Experiment 2 Reporting the Effect of This Combination | [8] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | EIF4EBP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Genistein enhanced the antitumor activity of cisplatin and reduced the expression of NF-kappaB, p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | APAF1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IFI27 | Molecule Info | |||
| In-vitro Model | P39 | CVCL_0478 | Melanoma | Homo sapiens | ||
| MeWo | CVCL_0445 | Cutaneous melanoma | Homo sapiens | |||
| A101D | CVCL_1057 | Melanoma | Homo sapiens | |||
| HM3KO | CVCL_5620 | Melanoma | Homo sapiens | |||
| P22 cell line | Melanoma | Homo sapiens | ||||
| Experimental
Result(s) |
Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells. | |||||
| Experiment 4 Reporting the Effect of This Combination | [7] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| Ca Ski | CVCL_1100 | Cervical squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Genistein enhances the anticancer effect of cisplatin in CaSki cells. | |||||
| Experiment 5 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
| A2780/C200 | CVCL_F638 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells. | |||||
| Experiment 6 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCCLM3 | CVCL_6832 | Adult hepatocellular carcinoma | Homo sapiens | ||
| In-vivo Model | Nude mice were injected subcutaneously in axilla area with 0.2 mL HCCLM3 cell suspension with a concentration of 2.5*107 /mL. | |||||
| Experimental
Result(s) |
Genistein reinforced the inhibitory effect of cisplatin on HCC cell proliferation and tumour recurrence and metastasis after curative hepatectomy in nude mice, possibly through mitigation of cisplatin-induced MMP-2 upregulation. | |||||
